Pharmacotherapy for Alcohol Dependence: Anticraving Medications for Relapse Prevention.
10.3349/ymj.2006.47.2.167
- Author:
Young Chul JUNG
1
;
Kee NAMKOONG
Author Information
1. Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea. keen@yumc.yonsei.ac.kr
- Publication Type:Review
- Keywords:
Alcohol dependence;
pharmacotherapy;
naltrexone;
acamprosate
- MeSH:
gamma-Aminobutyric Acid/metabolism;
Taurine/analogs & derivatives/therapeutic use;
Recurrence;
Receptors, Opioid, mu/genetics/metabolism;
Receptors, Opioid/antagonists & inhibitors;
Polymorphism, Genetic;
Neurons/metabolism;
Naltrexone/therapeutic use;
N-Methylaspartate/metabolism;
Models, Neurological;
Models, Biological;
Humans;
Glutamine/metabolism;
Disulfiram/therapeutic use;
Alcoholism/*drug therapy;
Alcohol Deterrents/*therapeutic use
- From:Yonsei Medical Journal
2006;47(2):167-178
- CountryRepublic of Korea
- Language:English
-
Abstract:
Alcohol dependence is a chronic disorder that results from a variety of genetic, psychosocial, and environmental factors. Relapse prevention for alcohol dependence has traditionally involved psychosocial and psychotherapeutic interventions. Pharmacotherapy, however, in conjunction with behavioral therapy, is generating interest as another modality to prevent relapse and enhance abstinence. Naltrexone and acamprosate are at the forefront of the currently available pharmacological options. Naltrexone is an opioid receptor antagonist and is thought to reduce the rewarding effect of alcohol. Acamprosate normalizes the dysregulation of N-methyl-D-aspartate (NMDA)-mediated glutamatergic excitation that occurs in alcohol withdrawal and early abstinence.These different mechanisms of action and different target neurotransmitter systems may endow the two drugs with efficacy for different aspects of alcohol use behavior. Since not all patients seem to benefit from naltrexone and acamprosate, there are ongoing efforts to improve the treatment outcomes by examining the advantages of combined pharmacotherapy and exploring the variables that might predict the response of the medications. In addition, novel medications are being investigated to assess their efficacy in preventing relapse and increasing abstinence.
